T1D, Metabolic Syndrome and Insulin Resistance

Clinical Characteristics in Adults With Type 1 Diabetes, Metabolic Syndrome and Insulin Resistance

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05503303

Enrollment

Registered

2022-08-16

Start date

2021-08-01

Completion date

2022-03-01

Last updated

2022-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Metabolic Syndrome, Type 1 Diabetes

Brief summary

Patients with type 1 diabetes (T1D) and metabolic syndrome (MS) require high doses of insulin to achieve a glycemic control, due to insulin resistance (IR). The investigators identified the presence of metabolic syndrome and insulin resistance in patients with T1D in a population of southeast Mexico. The sampled population was recruited from the Diabetes Clinic of the Regional Hospital of High Specialty Dr. Gustavo A. Rovirosa Pérez; from August 2021 to February 2022, graduated physicians interviewed patients previously diagnosed with T1D. This study included patients older than 18 years and at least six months after being diagnosed with T1D. The interviewers excluded patients who did not attend regular consultations and those who did not agree to participate or to give a blood sample. A diabetologist evaluated and diagnosed all patients based on the World Health Organization (WHO) criteria. Fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols were determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics. The reasearch team determined glycated hemoglobin concentrations by an enzymatic immunoassay method.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* At least six months after being diagnosed with T1D

Exclusion criteria

* Did not attend regular consultations * Did not agree to participate or to give a blood sample

Design outcomes

Primary

Measure	Time frame	Description
Glycated hemoglobin	March 2022	Concentrations by an enzymatic immunoassay method
Total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols	March 2022	Determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics

Countries

Mexico

Outcome results